Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors

Francesco Carrozza, Matteo Santoni, Francesco Piva, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, Rodolfo Montironi, Nicola Battelli, Stefano Tamberi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Telomerase activity and telomere length are essential for the pathogenesis of several human diseases, including genitourinary tumors. Telomerase constitutes a complex system that includes human telomerase reverse transcriptase (hTERT), human telomerase RNA component (hTR) and telomerase associated protein 1 (TEP1), which are overexpressed in tumor cells compared to normal cells and are involved in the carcinogenesis and progression of renal cell carcinoma (RCC), bladder (BC) and prostate cancer (PCa). In addition, telomerase degraded peptide fragments expressed on the surface of tumor cells lead to their recognition by immune cells. On this scenario, in vitro and in vivo studies have shown effective anti-tumor activity of hTERT-tailored strategies in genitourinary tumors, including active immunotherapy with hTERT-peptide vaccines and passive immunotherapy with hTERT-transduced T cell infusion. This review emphasizes the role of telomerase in the carcinogenesis and progression of genitourinary tumors, thus underlying the potential of emerging telomerase-tailored immunotherapies in these patients.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalCritical Reviews in Oncology/Hematology
Volume131
DOIs
StatePublished - Nov 1 2018

Fingerprint

Telomerase
Neoplasms
Carcinogenesis
Active Immunotherapy
Subunit Vaccines
Peptide Fragments
Passive Immunization
Telomere
Renal Cell Carcinoma
Urinary Bladder Neoplasms
Immunotherapy
Prostatic Neoplasms
T-Lymphocytes
human TERT protein
Proteins

Keywords

  • Bladder cancer
  • Immunotherapy
  • Prostate cancer
  • Renal cancer
  • Telomerases

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. / Carrozza, Francesco; Santoni, Matteo; Piva, Francesco; Cheng, Liang; Lopez-Beltran, Antonio; Scarpelli, Marina; Montironi, Rodolfo; Battelli, Nicola; Tamberi, Stefano.

In: Critical Reviews in Oncology/Hematology, Vol. 131, 01.11.2018, p. 1-6.

Research output: Contribution to journalReview article

Carrozza, F, Santoni, M, Piva, F, Cheng, L, Lopez-Beltran, A, Scarpelli, M, Montironi, R, Battelli, N & Tamberi, S 2018, 'Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors', Critical Reviews in Oncology/Hematology, vol. 131, pp. 1-6. https://doi.org/10.1016/j.critrevonc.2018.07.008
Carrozza, Francesco ; Santoni, Matteo ; Piva, Francesco ; Cheng, Liang ; Lopez-Beltran, Antonio ; Scarpelli, Marina ; Montironi, Rodolfo ; Battelli, Nicola ; Tamberi, Stefano. / Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. In: Critical Reviews in Oncology/Hematology. 2018 ; Vol. 131. pp. 1-6.
@article{3ccee1c34ce1462a8452b968455c07b3,
title = "Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors",
abstract = "Telomerase activity and telomere length are essential for the pathogenesis of several human diseases, including genitourinary tumors. Telomerase constitutes a complex system that includes human telomerase reverse transcriptase (hTERT), human telomerase RNA component (hTR) and telomerase associated protein 1 (TEP1), which are overexpressed in tumor cells compared to normal cells and are involved in the carcinogenesis and progression of renal cell carcinoma (RCC), bladder (BC) and prostate cancer (PCa). In addition, telomerase degraded peptide fragments expressed on the surface of tumor cells lead to their recognition by immune cells. On this scenario, in vitro and in vivo studies have shown effective anti-tumor activity of hTERT-tailored strategies in genitourinary tumors, including active immunotherapy with hTERT-peptide vaccines and passive immunotherapy with hTERT-transduced T cell infusion. This review emphasizes the role of telomerase in the carcinogenesis and progression of genitourinary tumors, thus underlying the potential of emerging telomerase-tailored immunotherapies in these patients.",
keywords = "Bladder cancer, Immunotherapy, Prostate cancer, Renal cancer, Telomerases",
author = "Francesco Carrozza and Matteo Santoni and Francesco Piva and Liang Cheng and Antonio Lopez-Beltran and Marina Scarpelli and Rodolfo Montironi and Nicola Battelli and Stefano Tamberi",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.critrevonc.2018.07.008",
language = "English (US)",
volume = "131",
pages = "1--6",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors

AU - Carrozza, Francesco

AU - Santoni, Matteo

AU - Piva, Francesco

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

AU - Battelli, Nicola

AU - Tamberi, Stefano

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Telomerase activity and telomere length are essential for the pathogenesis of several human diseases, including genitourinary tumors. Telomerase constitutes a complex system that includes human telomerase reverse transcriptase (hTERT), human telomerase RNA component (hTR) and telomerase associated protein 1 (TEP1), which are overexpressed in tumor cells compared to normal cells and are involved in the carcinogenesis and progression of renal cell carcinoma (RCC), bladder (BC) and prostate cancer (PCa). In addition, telomerase degraded peptide fragments expressed on the surface of tumor cells lead to their recognition by immune cells. On this scenario, in vitro and in vivo studies have shown effective anti-tumor activity of hTERT-tailored strategies in genitourinary tumors, including active immunotherapy with hTERT-peptide vaccines and passive immunotherapy with hTERT-transduced T cell infusion. This review emphasizes the role of telomerase in the carcinogenesis and progression of genitourinary tumors, thus underlying the potential of emerging telomerase-tailored immunotherapies in these patients.

AB - Telomerase activity and telomere length are essential for the pathogenesis of several human diseases, including genitourinary tumors. Telomerase constitutes a complex system that includes human telomerase reverse transcriptase (hTERT), human telomerase RNA component (hTR) and telomerase associated protein 1 (TEP1), which are overexpressed in tumor cells compared to normal cells and are involved in the carcinogenesis and progression of renal cell carcinoma (RCC), bladder (BC) and prostate cancer (PCa). In addition, telomerase degraded peptide fragments expressed on the surface of tumor cells lead to their recognition by immune cells. On this scenario, in vitro and in vivo studies have shown effective anti-tumor activity of hTERT-tailored strategies in genitourinary tumors, including active immunotherapy with hTERT-peptide vaccines and passive immunotherapy with hTERT-transduced T cell infusion. This review emphasizes the role of telomerase in the carcinogenesis and progression of genitourinary tumors, thus underlying the potential of emerging telomerase-tailored immunotherapies in these patients.

KW - Bladder cancer

KW - Immunotherapy

KW - Prostate cancer

KW - Renal cancer

KW - Telomerases

UR - http://www.scopus.com/inward/record.url?scp=85052451178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052451178&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2018.07.008

DO - 10.1016/j.critrevonc.2018.07.008

M3 - Review article

C2 - 30293699

AN - SCOPUS:85052451178

VL - 131

SP - 1

EP - 6

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -